Compare QLYS & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QLYS | TGTX |
|---|---|---|
| Founded | 1999 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.0B |
| IPO Year | 2012 | 1995 |
| Metric | QLYS | TGTX |
|---|---|---|
| Price | $128.86 | $31.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $139.43 | $51.60 |
| AVG Volume (30 Days) | 347.1K | ★ 2.4M |
| Earning Date | 02-05-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.91 | N/A |
| EPS | ★ 5.16 | 2.78 |
| Revenue | ★ $653,034,000.00 | $531,898,000.00 |
| Revenue This Year | $12.00 | $87.88 |
| Revenue Next Year | $7.68 | $47.78 |
| P/E Ratio | $24.97 | ★ $11.24 |
| Revenue Growth | 10.13 | ★ 100.88 |
| 52 Week Low | $112.61 | $25.28 |
| 52 Week High | $155.47 | $46.48 |
| Indicator | QLYS | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.34 | 55.99 |
| Support Level | $131.00 | $29.80 |
| Resistance Level | $134.30 | $33.24 |
| Average True Range (ATR) | 3.53 | 1.66 |
| MACD | -0.08 | 0.33 |
| Stochastic Oscillator | 18.03 | 71.18 |
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.